



SHOFU INC.

Financial Results Briefing for the Fiscal Year Ended March 2025

May 20, 2025

Event Summary

[Company Name]	SHOFU INC.	
[Company ID]	7979-QCODE	
[Event Language]	JPN	
[Event Type]	Earnings Announcement	
[Event Name]	Financial Results Briefing for the Fiscal Year Ended March 2025	
[Fiscal Period]	FY2025 Annual	
[Date]	May 20, 2025	
[Number of Pages]	38	
[Time]	15:30 – 16:30 (Total: 60 minutes, Presentation: 46 minutes, Q&A: 14 minutes)	
[Venue]	Webcast	
[Venue Size]		
[Participants]		
[Number of Speakers]	2	
	Tetsuo Takami	President and COO
	Fumitaka Yamazaki	Director, Senior Managing Executive Officer, Corporate Planning

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Presentation

Moderator: As it is time, we will now begin the financial results briefing for SHOFU INC. for the fiscal year ended March 2025. Thank you very much for taking the time out of your busy schedules to attend today's briefing.

First, let me introduce the Company representatives present today. Representing the Company are President and CEO, Tetsuo Takami, and Director and Senior Executive Officer, Fumitaka Yamazaki.

Today's presentation will proceed as follows. Mr. Yamazaki will begin by explaining the summary of the full year financial results for FY2025 and the earnings forecast for the current fiscal year. This will be followed by President Takami's update on the progress of the fifth medium-term management plan.

Before we begin, we would like to share a few announcements. This briefing includes a Q&A session. Questions will be accepted via the Q&A function on the control panel in text format until 4:10 PM.

Questions submitted will not be visible to other participants and will be read aloud by our staff.

If you prefer to remain anonymous, please indicate so when submitting your question. We will start the Q&A session around 4:10 PM, during which we will read and respond to the submitted questions. Please note that we may not be able to answer all questions due to time constraints. The chat function is disabled, so if you encounter any issues, please notify us via the Q&A function.

Now I would like to hand it over to Director and Senior Executive Officer Yamazaki for an overview of the FY2025 full year financial results and the earnings outlook for this fiscal year.

Yamazaki: Good afternoon, everyone. I am Fumitaka Yamazaki, Senior Executive Officer. Thank you very much for joining SHOFU's financial results briefing today.

As the moderator just explained, today's session is divided into two parts. In the first part, I will cover the overview of the financial results for FY2025 and the earnings forecast for FY2026.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Financial Summary

■ Financial Summary



FYE3/25 results

Net sales ¥38,698mn (Overseas sales 58.6%)
Operating income ¥5,392mn

- Earnings were largely in line with the plan. Sales increased 10.3% YoY due to sales growth overseas in existing products, increased demand for *SHOFU Block PEEK* due to inclusion in health insurance coverage, and foreign exchange effects (weaker yen)
- Operating income increased 14.5% YoY, mainly driven by higher sales, which offset a sharp rise in SG&A expenses due to upfront investments and a bolstering of sales activities. Favorable foreign exchange rates (weaker yen) also contributed to the profit growth

FYE3/26 outlook

Net sales ¥40,876mn (Overseas sales 58.6%)
Operating income ¥4,800mn

- We expect sales to increase by 5.6% YoY due to continued sales growth in Japan and overseas in existing products (mainly filling and restoration materials and CAD/CAM materials), as in the previous period. Assumptions are premised on a stronger yen than current forex rates (Forex assumptions: ¥140.00/\$, ¥150.00/€, ¥20.00/RMB)
- **Expect sales to reach a record high for the fifth consecutive FYE. We also expect profits to remain at a high level.**

Shareholder returns

Dividend policy: Payout ratio of 40%+ and DOE of 3.0%+ on a consolidated basis

- Dividend for FYE3/25: ¥36 (interim) / ¥31 (year-end) per share (¥98 annual total on a pre-stock split basis)
- Dividend forecast for FYE3/26 : ¥53/share (Up ¥8 from the previous year on a pre-stock split basis)

* A 2-for-1 stock split of the common shares was effected on October 1, 2024.

3

Let me begin with the financial summary.

For FY2025, net sales were JPY38.698 billion and operating profit was JPY5.392 billion. We achieved both top line and bottom-line growth YoY, landing nearly in line with our expectations.

Sales remained solid both in Japan and overseas. The impact of foreign exchange, particularly the weaker yen, contributed positively to overseas sales, resulting in a 10.3% YoY increase in total sales.

On the profit side, although the gross profit margin declined by 0.4 percentage point and selling, general, and administrative expenses increased by JPY1.3 billion, the rise in revenue led to a 14.5% increase in operating profit. The impact of foreign exchange fluctuations on net sales was a positive JPY1.074 billion and on operating profit, a positive JPY444 million.

Moving on to the forecast for FY2026, we expect continued solid growth in both domestic and overseas sales. However, we have assumed a stronger yen in our forex assumptions, so nominal growth in sales appears moderate, but in real terms, we anticipate growth exceeding the previous year.

On the profit side, while revenue is expected to increase, SG&A expenses are also projected to rise, resulting in a forecasted 2.9% decrease in operating profit. The impact of foreign exchange fluctuations on net sales is expected to be negative JPY1.825 billion and on operating profit, negative JPY625 million.

As in the previous fiscal year, we plan to continue selling policy-holding shares, which will result in the posting of extraordinary gains and lead to an increase in net income.

Support

Japan 050.5212.7790

Tollfree 0120.966.744

Email Support support@scriptsasia.com



3

Regarding shareholder returns, we revised our dividend policy starting FY2025 to a payout ratio of 40%. As a result, the dividend for FY2025 is planned at JPY98 per share, pre-stock split basis, and for FY2026, JPY106 per share.

■ Consolidated Financial Results for FYE3/25

Key earnings highlights for FYE3/25



	FYE 3/24 Actual		FYE 3/25 Actual		Change YoY		FYE 3/25 Forecast	
	(% of sales)		(% of sales)		(% change)		(% change)	
Net sales	35,080	(100.0)	38,698	(100.0)	3,617	(10.3)	38,395	(100.8)
(Domestic sales)	14,892	(42.5)	16,012	(41.4)	1,120	(7.5)	15,912	(100.6)
(Overseas sales)	20,188	(57.5)	22,685	(58.6)	2,497	(12.4)	22,483	(100.9)
Gross profit	20,995	(59.8)	22,991	(59.4)	1,996	(9.5)	23,081	(102.6)
(SG&A)	16,286	(46.4)	17,599	(45.5)	1,312	(8.1)	17,787	(98.9)
Operating income	4,709	(13.4)	5,392	(13.9)	683	(14.5)	5,293	(101.9)
Ordinary income	5,118	(14.6)	5,523	(14.3)	404	(7.9)	5,604	(98.5)
Net income	3,655	(10.4)	4,317	(11.2)	661	(18.1)	4,434	(97.4)
EPS	103.09		121.52		18.43		124.87	
ROE	9.5%		10.3%		0.8ppt		10.4%	
Forex								
\$	144.40		152.48		8.08		145.09	
€	156.80		163.62		6.82		155.65	
RMB	19.80		21.03		1.23		20.11	

Effect of forex fluctuations: Net sales +¥1,074mn (vs previous FYE)
Net income = net income attributable to owners of parent
FYE3/25 Forecast = revised plan announced on August 2, 2024.

5

Next, I will provide a more detailed explanation of the FY2025 results.

This slide presents the FY2025 performance compared to the previous fiscal year, along with reference forecasts.

Net sales increased 10.3% YoY to JPY38.698 billion, with domestic sales up 7.5% and overseas sales up 12.4%. The impact of foreign exchange fluctuations was a positive JPY1.074 billion. Excluding this effect, overseas sales rose 7.1% on a local currency basis, and the combined domestic and overseas growth was 7.2%.

The main factor behind the increase in domestic sales was higher sales of CAD/CAM materials for molars, specifically PEEK BLOCKs, which were covered by insurance starting in December two years ago, along with increased sales of CAD/CAM-related equipment.

For overseas sales, processed products saw steady growth across all regions. Including this contribution, sales in China, North America, and Central and South America all posted double-digit growth in local currencies. Together with the positive impact of foreign exchange, overseas sales rose 12.4%.

Gross profit margin declined by 0.1 percentage point, despite positive factors, such as an increase in the proportion of overseas sales and processed products. This decline was due to expanding sales in emerging markets, decreased sales in the nail business, and a drop in resin tooth sales in China. Selling, general, and administrative expenses rose by approximately JPY1.3 billion, including foreign exchange effects. Excluding

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptasia.com



currency effects, the increase was 5.9%, which reflects a normal rise associated with business expansion activities. As a result, operating profit increased by 14.5%.

In nonoperating income and expenses, a foreign exchange gain of JPY225 million in the previous year turned into a loss of JPY110 million this year. Consequently, the increase in ordinary profit was narrower than that of operating profit. However, with the posting of a special gain of JPY661 million from the sale of policy-holding shares, net income rose by 18.1%.


Since both net sales and profits came in nearly as expected, I will omit further explanation on the forecast comparison.

Note that the earnings per share displayed on this page reflects the assumption that the two-for-one stock split conducted in October 2024 had occurred at the beginning of the previous fiscal year.

■ Consolidated Financial Results for FYE3/25



Operating income (YoY)



6

Next, I will speak about the earnings structure.

Against the JPY3.617 billion increase in net sales, operating profit rose by JPY683 million. Although the gross margin declined by 0.4 percentage point, the SG&A ratio improved by 0.9 percentage point. As a result, the operating margin rose by 0.5 percentage point to 13.9%, marking record highs in both value and ratio.

Support


Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com





Net sales by product category (YoY)



- ▶ **Artificial Teeth Products**
CAD/CAM zirconia disks and ceramic materials remained strong overseas, while sales of some resin teeth slowed due to rising competition
- ▶ **Chemical Products (Filling/restorative materials, CAD/CAM resin blocks, crown materials)**
Supply constraints resolved through enhanced procurement channels and expanded production; sharp YoY growth driven by resumption of aggressive overseas promotions
- ▶ **Machinery, Equipment & Other Products**
Domestic CAD/CAM machines and EyeSpecial C-V (digital dental camera) sold well both in Japan and overseas

7

Slide seven shows net sales by product category.

The growth in sales was driven by processed products, which performed steadily across all regions.

Domestically, sales were led by CAD/CAM resin blocks and PEEK materials. Overseas, sales were centered on filling and restorative materials, as well as hard resin materials for crowns and bridges.

Regarding processed products, the expansion of raw material procurement channels and the establishment of a mass production framework resolved supply constraints, enabling the resumption of aggressive sales promotion activities, particularly overseas.

The CAD/CAM resin blocks and PEEK materials, which can now be used for all molars, became eligible for insurance coverage in December 2023. This means CAD/CAM resin block treatment is now covered by insurance for all tooth areas. Although there are 6 million cases eligible for treatment using PEEK, our sales volume remains at around 200,000 units. Moreover, the overall transition rate to CAD/CAM treatment is still just 20%, indicating significant growth potential in this field.

Other notable points are listed on the slide.

Support


Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com





Net sales by region (YoY)



	FYE 3/25		Change YoY(%)	
	Actual	Composition	¥ basis	LCY basis
Japan	16,012	41.4%	7.5%	7.5%
Overseas	22,685	58.6%	12.4%	7.1%
North & Latin America	5,002	12.9%	15.9%	10.1%
Europe	7,969	20.6%	10.2%	5.3%
China	5,689	14.7%	19.3%	12.3%
Asia ex-China & Oceania	4,025	10.4%	4.0%	0.5%
Total	38,698	100.0%	10.3%	7.2%

*Europe : Includes Middle East and Africa

▶ Japan	Strong sales of CAD/CAM-related materials, especially SHOFU Block PEEK, and peripheral equipment
▶ Overseas	Global : Restorative materials, mainly Giomer products, remained solid
	+
North & Latin America	: Sales of abrasive materials showing recovery
Europe	: Strong performance in CAD/CAM materials; business expansion progressing in the Middle East
China	: Some artificial teeth product sales slowed due to higher competition, but crown materials performed well
Asia ex-China & Oceania	: Surge in demand for materials in India has settled down

8

Slide eight shows sales by region.

In Japan, sales of CAD/CAM-related materials and peripheral devices, particularly SHOFU BLOCK PEEK, performed well.

Overseas, sales of filling and restorative materials were strong across all regions, resulting in double-digit growth on a local currency basis. Other notable items are as listed on the slide. Please note that the Europe and Other Asia regions include sales to the Middle East and Africa. Combined sales in these regions totaled JPY838 million, representing a 5.7% YoY increase on a local currency basis.

Support


Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptasia.com





Operating income swing factors (YoY)



9

Slide nine illustrates the factors behind changes in operating profit.

Positive factors included increased sales and the impact of foreign exchange fluctuations. Negative factors were the rise in the cost-of-sales ratio and the increase in SG&A expenses.

Regarding the rise in the cost-of-sales ratio, although there were positive factors, such as a higher proportion of overseas sales and processed products, it was affected by expanding sales in emerging markets, a decline in nail business revenue, and lower resin tooth sales in China.

SG&A expenses increased due to active business development and were also affected by temporary costs, such as provision for doubtful accounts and cultural heritage excavation expenses. Nevertheless, operating profit increased by 14.5%.

Although not shown in the slides, we have changed the depreciation method from the declining-balance method, to the straight-line method, starting this fiscal year. This change had a positive impact of JPY150 million on operating profit.

Among the effects of foreign exchange fluctuations, the portion labeled “consolidation adjustments” reflects changes due to an increase in unrealized gains on inventory, not related to actual goods movement. This profit, which is usually deducted, decreased this time.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Balance sheet

Consolidated Financial Results for FYE3/25



(¥mn)



High equity ratio (82.7%):

Pursuing capital efficiency while maintaining a sound and resilient financial base

- ✓ Total assets (-¥99mn): Investment securities decreased due to decline in market value
- ✓ Net assets (+¥1,126mn): Retained earnings increased reflecting profit accumulation

10

Slide 10 shows the balance sheet.

Total assets decreased due to a decline in the market value of investment securities. Liabilities also declined, primarily due to a decrease in deferred tax liabilities related to valuation differences on available-for-sale securities, following both the sale of securities and the decline in their prices. Borrowings were also reduced through ongoing repayments.

Net assets increased through retained earnings, while valuation differences on securities decreased, resulting in a net increase of JPY1.126 billion.

The increase in inventories was mainly due to a temporary rise in purchased goods under a supply agreement on a standalone basis. Overseas inventories remained roughly at the previous year's level despite expanding sales.

Among investment securities, we sold five policy-holding stocks during the year. Combined with a drop in share prices, the value of such holdings declined from JPY8.899 billion at the end of the previous year, to JPY6.146 billion at the end of this year. Their share of total net assets dropped to 14.4%.

Together with loan repayments, the equity ratio improved from 82.7% to 85.2% YoY.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com




Cash flows

Consolidated Financial Results for FY3/25



(¥mn)



11

Slide 11 presents the cash flow.

Compared to the previous fiscal year, operating cash flow increased by JPY358 million due to a rise in income before income taxes and other factors. Investment cash flow increased by JPY381 million due to a decrease in purchases of property, plant, and equipment. As a result, free cash flow rose by JPY739 million.

We sold five policy-holding stocks, fully divesting four of them. The resulting gain of JPY869 million was used to increase dividend payments and repay borrowings.

The shareholder return ratio against free cash flow was 54.7%.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com





Summary of full-year forecasts

- Seeking balanced growth across all regions, with a focus on chemical products and overseas markets
- Unlike the previous FYE, which benefited from forex tailwinds, the current plan is based on a stronger yen. Operating and ordinary income are projected to decline, **but we expect growth in the topline and in net income, due to business growth**

We expect new all-time highs for sales and net income despite the stronger yen

- Actively investing in production facilities
- Steady progress in line with the medium-term plan, supported by rising overseas sales ratio and business expansion across regions, enhancing confidence in achieving MTP targets

Initiatives in place are showing tangible results toward the realization of the current medium-term management plan

- Strengthening the foundation for long-term corporate value through restructuring of production and supply systems, and the recruitment and development of talent
- Building an organization that can flexibly respond to regulatory changes and policy shifts across regions, preventing any gaps in business operations

Full-scale preparations underway to create a solid management base for the future

13

Next, I will explain the earnings outlook for FY2026.

This slide summarizes the qualitative factors and trends that form the basis of our full year forecast.

Net sales are expected to reach a new record high for the fifth consecutive year. Operating profit and ordinary profit are projected to decline due to an assumed appreciation of the yen. However, excluding the effects of foreign exchange, the underlying trend remains one of profit growth.

Net income is also expected to hit a record high for the sixth consecutive year, driven by continued sales of policy-holding shares, as in the previous fiscal year.

FY2026 marks the second year of the fifth medium-term management plan announced last year. Although sales are forecast to fall slightly short of the plan, profit is expected to exceed the target.

As for growth investments, our key products are progressing as planned, which supports our current assumptions, and we do not intend to revise the plan at this time. We will continue building a structure and system that can respond swiftly and flexibly to future changes in demand and business risks.

The impact of US tariffs is not reflected in our current forecast. As we have no production facilities in the US, we export from Japan, China, and Vietnam, and we expect to be affected to some extent.

However, while keeping an eye on competitors' pricing strategies, we are considering passing on some costs to customers. Furthermore, some US competitors manufacture outside the US, and if US firms lose competitiveness in China, this could strengthen our own competitive position.

Support

Japan 050.5212.7790

Tollfree 0120.966.744

Email Support support@scriptsasia.com



In addition, our growth has not been overly dependent on the US. We have grown in a well-balanced manner across Europe, China, and other parts of Asia, which has strengthened our overall resilience to changes in national policies and economic conditions.

That said, many uncertainties remain, making it difficult to provide a highly reliable forecast at this point. Once more definitive information becomes available, we will assess its impact on our performance and revise the forecast if necessary.

■ Financial Forecasts for FYE3/26

Comparison of key metrics



(¥mn, %)

	FYE 3/25 Actual		FYE 3/26 Forecast		Change YoY	
	(% of sales)		(% of sales)		(% change)	
Net sales	38,698	(100.0)	40,876	(100.0)	2,178	(5.6)
(Domestic sales)	16,012	(41.4)	16,931	(41.4)	919	(5.7)
(Overseas sales)	22,685	(58.6)	23,945	(58.6)	1,259	(5.6)
Gross profit	22,991	(59.4)	24,253	(59.3)	1,261	(5.5)
(SG&A)	17,599	(45.5)	19,016	(46.5)	1,417	(8.1)
Operating income	5,392	(13.9)	5,236	(12.8)	- 156	(-2.9)
Ordinary income	5,523	(14.3)	5,363	(13.1)	- 159	(-2.9)
Net income	4,317	(11.2)	4,701	(11.5)	384	(8.9)
EPS	121.52		132.28		10.76	
ROE	10.3%		10.9%		0.6ppt	
Forex						
\$	152.48		140.00		- 12.48	
€	163.62		150.00		- 13.62	
RMB	21.03		20.00		- 1.03	

*Effect of forex fluctuations (YoY): Net sales -¥1,825mn

*Net income = net income attributable to owners of parent

14

Slide 14 presents our key financial indicators.

Net sales are expected to decline by JPY1.825 billion due to foreign exchange assumptions, making the top line forecast appear somewhat conservative. However, we anticipate steady performance in both domestic and overseas markets.

Gross profit margin is expected to decline by 0.1 percentage point YoY. SG&A expenses are projected to rise by JPY1.417 billion. Combined with foreign exchange effects, operating profit is expected to decrease by 2.9% YoY, with the operating margin falling to 12.8%. However, excluding the impact of foreign exchange fluctuations, the operating margin would be 13.7%.

Due to the decline in operating profit, ordinary profit is also expected to fall by a similar margin.

As mentioned earlier, we expect to record a special gain of JPY1.128 billion from the sale of investment securities, an increase of JPY446 million YoY. As a result, net income is projected to rise by 8.9%.

Support

Japan 050.5212.7790


Tollfree 0120.966.744

Email Support support@scriptsasia.com





Net sales by product category (YoY)



15

Slide 15 shows net sales by product category.

As in previous years, processed products are expected to continue driving growth. However, we also anticipate solid growth in materials, such as artificial teeth, abrasives, and cements.

For processed products, we expect growth of just under 10% on a local currency basis in North America, Central and South America, and Europe, while growth in China and Asia are projected to exceed 20%, reflecting a greater contribution from emerging markets.

Support


Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com





Net sales by region (YoY)



Units: ¥mn

	FYE 3/26		Change YoY(%)	
	Forecast	Composition	¥ basis	LCY basis
Japan	16,931	41.4%	5.7%	5.7%
Overseas	23,945	58.6%	5.6%	13.6%
North & Latin America	5,345	13.1%	6.9%	16.3%
Europe	8,175	20.0%	2.6%	11.4%
China	6,210	15.2%	9.2%	14.8%
Asia ex-China & Oceania	4,214	10.3%	4.7%	12.8%
Total	40,876	100.0%	5.6%	10.3%

*Europe : Includes Middle East and Africa

- ✓ Underlying growth expected in all regions; overseas sales projected to grow over 10% ex. forex
- ✓ Balanced growth expected in all regions, led by Japan, Europe, and China; steady expansion in Asia
- ✓ Closely monitoring US tariff policies and US-China trade tensions; swift response planned if any impact materializes

16

Slide 16 shows net sales by region.

In Japan, we anticipate expanding demand for resin blocks made from PEEK, applicable to molars, as well as growth in peripheral materials, such as bonding systems.

Overseas, we expect 10% growth across all regions in local currency terms.

As mentioned in Slide 15, we expect strong growth across all regions. In addition to this, we anticipate increased sales in North and Central/South America of artificial teeth, zirconia-based CAD/CAM materials, and abrasive materials, including Vietnam-made diamond abrasives. In Europe, we also expect growth in zirconia-based CAD/CAM materials and artificial teeth from Merz Dental. In Asia, we anticipate increased sales of porcelain materials from India, which are classified as artificial teeth, as well as Vietnam-made diamond abrasives.

As for the economic slowdown in China and the effects of domestic production incentives, we have not observed any significant impact at this time.

Support


Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com





Operating income swing factors (YoY)



17

Slide 17 outlines the factors contributing to changes in operating profit.

Although we anticipate the positive effects of higher sales and a slight decrease in the cost-of-sales ratio, operating profit is expected to decline YoY. This is due to continued proactive efforts in market development and sales force enhancement, both domestically and internationally, as well as increased R&D investment, all of which will result in higher SG&A expenses. In addition, the negative impact of foreign exchange assumptions based on a stronger yen will also weigh on profits.

While there are positive factors for the cost-of-sales ratio, such as an increased proportion of processed products, personnel investments to adjust working arrangements due to delays in factory construction, as well as broader investments in workforce for future production system development have limited the extent of the decline in the cost-of-sales ratio.

As for the increase in SG&A expenses, the main driver of higher personnel costs is the strengthening of sales structures in various overseas regions, leading to an overall increase in personnel costs of approximately 11%.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com





Forex impact

FYE 3/26 Forecast

Units: ¥mn

	Forex rate		Consolidated earnings impact		Per yen of ¥1 strength	
	FYE 3/25	FYE 3/26 Forecast	Sales	Operating income	Sales	Operating income
USD	152.48	140.00	-593	-278	-47	-22
EUR	163.62	150.00	-656	-254	-48	-18
RMB	21.03	20.00	-319	-220	-310	-195

- ✓ FY3/26 guidance assumes YoY appreciation (\$:¥12.48 appreciation YoY)
- ✓ Overseas sales ratio is on an upward trend; yen appreciation will have a negative impact on performance (\$: Every ¥1 of yen appreciation against the yen drags down sales by ¥47 million and operating income by ¥22 million)

18

Slide 18 illustrates the impact of foreign exchange fluctuations.

For this fiscal year, our assumed exchange rates are JPY140 to the US dollar, JPY150 to the euro, and JPY20 to the yuan. The expected impact of these three currencies on operating profit totals JPY754 million, and the total impact of foreign exchange fluctuations on operating profit is expected to be JPY796 million.

A stronger yen is a negative factor. The impact of a JPY1 appreciation on both net sales and operating profit is shown on the slide.

Support

Japan 050.5212.7790
Tollfree 0120.966.744


Email Support support@scriptsasia.com





Dividend policy

【Target】 Consolidated dividend payout ratio: 40% or more DOE: 3.0%



19

To conclude the first half of this presentation, I will now explain our dividend policy.

Starting from FY2025, we revised our dividend policy, setting a target payout ratio of 40% or higher and a target DOE of 3%.

For FY2025, the dividend increased by JPY18 compared to the previous fiscal year on a post-stock split basis, from JPY31 to JPY49. For FY2026, we plan to increase the dividend by a further JPY4, bringing it to JPY53.

Regarding the repurchase of treasury stock, which we are frequently asked about by investors, we are not considering it at this time. The reasons are twofold. First, our shares have relatively low liquidity in the market, making share repurchase through market transactions inappropriate, and second, we are in a phase of actively investing for future growth, which requires capital.

That concludes the first part of our presentation. Thank you for your attention.

Next, President and CEO Takami will provide an update on the progress of the fifth medium-term management plan.

Takami: I am Tetsuo Takami, President and CEO of SHOFU. Once again, thank you very much for attending today's financial results briefing.

I would now like to explain the progress made in the first year of SHOFU Group's fifth medium-term management plan, which was announced on May 1 of last year.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com





Today’s explanation will cover an overview of the fifth medium-term management plan, our progress during the first year, and our ongoing initiatives toward realizing our long-term vision.

Let me begin with an outline of the current fifth medium-term management plan.

Achieving our long-term vision of sales of ¥50bn

- Our new medium-term management plan targets sales of ¥50bn*, a target we first formulated in 2012
- Capex and investment of ¥15.3bn over 4 years. Proactively make upfront and growth investments to strengthen the production system, with an eye on the next-stage of our business expansion
- Investments will be funded from operating CF, sales of strategic shareholdings, and debt financing. We will flexibly review the cash position
- Enhance shareholder returns. Raise dividend payout ratio to 40% and DOE to 3.0% or more

*In addition to group sales of ¥50bn, we also targeted operating income of ¥7.5bn (operating margin: 15%)

23

This slide summarizes the key points of the ongoing fifth medium-term management plan that we particularly wish to share with you.

First, we expect to achieve our long-term vision of “JPY50 billion in group net sales” during the period covered by this medium-term plan.

While our past medium-term plans were generally structured over a three-year period, this time we have set a four-year plan to ensure the firm achievement of this target.

The main pillar supporting this goal is active investment in production facilities. To strengthen our groupwide production capabilities and lay the foundation for future business expansion, we plan to make growth investments totaling JPY15.3 billion, the largest in our history.

The funding will come from a combination of operating cash flow, the sale of policy-holding shares, and appropriate debt financing, all executed under a sound capital structure.

At the same time, we are working to enhance shareholder returns. We have raised our target dividend payout ratio from 30% to 40%, and our target DOE from 1.7% to 3% or higher, aiming to balance sustainable corporate value creation with returns to our shareholders.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com

Key numerical targets



(¥mn)

	FYE3/25 Actual	vs. Initial Plan	FYE3/26 Forecasts	vs. Initial Plan	Medium-Term Management Plan	
					FYE3/27	FYE3/28
Net sales	★ 38,698	976 ↑	★ 40,876	-163 ↓	★ 45,151	★ 50,185
(YoY)	(10.3%)		(5.6%)		(10.5%)	(11.1%)
(Domestic sales)	★ 16,012	-158 ↓	★ 16,931	139 ↑	★ 17,739	★ 18,733
(YoY)	(7.5%)		(5.7%)		(4.8%)	(5.6%)
(Overseas sales)	★ 22,685	1,134 ↑	★ 23,945	-302 ↓	★ 27,411	★ 31,452
(YoY)	(12.4%)		(5.6%)		(14.5%)	(14.7%)
Operating income	★ 5,392	592 ↑	5,236	105 ↑	★ 6,325	★ 7,531
(% of sales)	(13.9%)		(12.8%)		(14.0%)	(15.0%)
Ordinary income	★ 5,523	629 ↑	5,363	108 ↑	★ 6,450	★ 7,663
(% of sales)	(14.3%)		(13.1%)		(14.3%)	(15.3%)
Net income	★ 4,317	478 ↑	★ 4,701	196 ↑	★ 5,488	★ 6,734
(% of sales)	(11.2%)		(11.5%)		(12.2%)	(13.4%)
Dental business overseas sales ratio	★ 59.8%		★ 60.1%		★ 62.1%	★ 64.0%

★ Record highs

25

Next, I will explain the progress made in the first year of the medium-term management plan.

This slide shows the previous fiscal year's actual results, the first year, the current fiscal year's outlook, and the targets set for FY2027 and FY2028 at the time the plan was formulated.

As Mr. Yamazaki mentioned earlier, despite some variances due to exchange rates, both the previous year's results and the current year's forecast are progressing generally in line with the medium-term plan. We will continue to make flexible and agile management decisions to ensure that we meet our targets.

In terms of cumulative numerical targets over the plan period, we project average annual growth of over 9% in net sales and over 11% in overseas sales. Overseas operations will continue to drive overall performance, while domestic operations are expected to achieve steady growth, backed by a stable business foundation.

Profits are also expected to trend upward. With improvements in the gross profit margin and a relatively moderate increase in SG&A expenses compared to sales growth, we forecast an operating margin of 15% in the final year of the plan.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Key issues to address



Further progress with initiatives from the previous plan

01	Develop and launch new products aligned with local demand and needs
02	Development of sales network and sales offices
03	Develop domestic and international academic networks (create a structure through which we can directly promote products to users)
04	Cost reductions, reallocation of production sites to allow increased production volumes, expansion of overseas production
05	Attracting and training talent for the proactive development of our overseas business

26

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Key issues to address



Adding promotion of sustainability management as a key management issue

06	Financing to meet growing demand for capital
07	M&A (business and technology alliances, business acquisitions)
08	Strengthening the group governance structure
09	Business alliance with Mitsui Chemicals, Inc. and Sun Medical, Inc.
10	Promotion of sustainability management

27

Achieving this plan requires overcoming several challenges. As listed on this slide, these include initiatives in R&D, sales, production, and human resources. Additionally, we have newly added the promotion of sustainability-focused management as a key management issue.

Now I will highlight the challenges that require particular focus and discuss our progress in the first year.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com




Key issues to address



01

Develop and launch new products aligned with local demand and needs



Proactive and ongoing investment as a R&D-oriented company

- Promote product development from a global perspective
- Product development targeting the middle class and volume zone
- Product development aimed at creating markets in new fields
- Aim to achieve and maintain a new product sales ratio of 20%

28

This slide explains our initiatives in research and development.

As a development-driven company, we position ongoing and active R&D investment as a core management pillar.

Our product development policy focuses on three key areas, global-oriented development, product offerings for the middle-income and volume zones, and entering new fields that lead to the creation of new markets. At the same time, we are also working on improving existing products.

Recent new product groups include the self-adhesive resin cement “BeautiLink SA,” the dental digital camera “EyeSpecial C-V,” CAD/CAM crown materials now covered by insurance for molars, and SHOFU BLOCK PEEK. All of these have been receiving favorable market response.

In FY2025, the first year of the plan, the ratio of new product sales was 14.6%, unfortunately falling short of the previous year’s level.

This decline was partly due to the fact that, under our definition of new products as those launched within the past 36 months, some previously high-selling items no longer qualified.

Additionally, newer products have yet to reach full market maturity. Within the R&D division, we recognize the need to accelerate development timelines, while the sales division is focused on speeding up market penetration.

That said, the creation of new products remains a central initiative supporting our growth. We will maintain our target of achieving a 20% new product sales ratio and continue treating this as a key strategic priority.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptasia.com



23

Going forward, we will work to launch new products in overseas markets and accelerate sales efforts, both domestically and internationally, to achieve our 20% target.

Key issues to address



02

Development of sales network and sales offices

03

Develop domestic and international academic networks (create a structure through which we can directly promote products to users)



In-House Dental Technician Seminar (Nov. 2024)



Exhibited at IDS 2025 in Germany

The SHOFU Group brand recognition remains low, particularly overseas
Large growth potential through business expansion in high quality services and products

Japan

- Aim to expand market share in filling and restoration materials, CAD/CAM materials, and preventive and care products

Overseas

- Set up new offices and secure staff in major countries and regions
- Expansion of distributor network in Europe, Middle East and Africa

29

Next, I would like to explain our key initiatives in the sales domain.

Starting with the domestic market, in fields such as artificial teeth and abrasives, our brand recognition is high, thanks to years of consistent efforts, and we continue to maintain the top market share.

On the other hand, in areas, such as filling and restorative materials, and CAD/CAM materials, we believe there is still significant room for growth. We therefore consider these to be priority areas for future expansion.

Traditionally, dental care has been strongly associated with treatment. However, in recent years, societal awareness has been shifting toward recognizing the broader role of dentistry, including prevention and daily self-care.

Discussions have begun around implementing nationwide dental checkups in Japan, and we believe the preventive dentistry market is certain to expand moving forward.

Against this backdrop, we have renewed our dental care brand, MERSSAGE, and significantly expanded our lineup of toothpaste products.

These products are designed to maximize their effectiveness when used under the guidance of dental professionals, and we aim to contribute to public oral health by promoting their use through dental clinics.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



In overseas markets, we recognize that our brand awareness remains limited. However, we are confident that the quality of our products and level of service are fully competitive with other players in the market, and we see significant growth potential.

Accordingly, we are expanding our presence and strengthening our academic sales force in each country and region.

Additionally, in Europe, the Middle East, and Africa, we are working to expand our distributor network and establish a structure that enables faster delivery of our products.

Key issues to address



04

Cost reductions, reallocation of production sites to allow increased production volumes, expansion of overseas production

Record investment in production facilities in Japan and overseas will increase production volume and production efficiency



Head office plant (outline)
Start of operation Phase 1: 2026
(scheduled) Phase 2: 2027



(Second production site in China)
SHOFU PRODUCTS CHANGZHOU CO., LTD
Scheduled start of operation: 2026



Shiga Shofu
(Shiga)



Shofu Products Kyoto,
(Kyoto)

Introduction of new equipment
Expansion of existing facilities

	FYE3/25	FYE3/26	FYE3/27- FYE3/28	Total amount
Normal equipment renewal	1.1	1.9	2.4	5.6
Reconstruction of the Kyoto head office plant	0.2	2.1	1.2	3.6
Domestic production sites	0.0	0.0	3.1	3.1
Overseas production/logistics sites	0.0	0.5	2.5	3.1
Total	1.4	4.6	9.4	15.5



SHOFU Products Vietnam
(Vietnam)

30

Next, I will explain our efforts to strengthen our production system.

Currently, demand for our products is very strong, and the business environment remains highly favorable. For this reason, it is no exaggeration to say that future business expansion hinges on how effectively we can establish and enhance our production and supply systems.

In this medium-term management plan, we are targeting JPY50 billion in net sales for FY2028, the final year of the plan. This represents approximately 1.3 times the JPY38.6 billion in sales achieved in FY2025.

To reach this level, strengthening our production capacity is essential, and we are committed to making proactive and sustained investments to achieve it.

Specifically, over the four years, from FY2025 to FY2028, we plan to invest approximately JPY9 billion in domestic and overseas production facilities, the largest such investment in our history. In the field of processed products, in particular, we plan to rebuild two buildings at our headquarters factory to

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



approximately double our current production capacity. We will also pursue greater efficiency and automation to establish an even larger-scale production system.

In China, we have established a new production base in Changzhou to serve as a supply hub for local market products.

At our domestic subsidiaries, we are proceeding with the transfer of certain products and processes from our headquarters factory. Together with our Vietnam facility, we will build an efficient global production network through optimal allocation.

Regarding the reconstruction of our headquarters factory, archaeological surveys of buried cultural assets by the City of Kyoto are required, which has caused some delays in certain processes. However, we expect to complete all work within the timeframe of the current medium-term management plan.


Through these initiatives, we aim to ensure a stable supply, achieve steady top line growth, and build a production foundation that will support further future expansion.

Key issues to address



10

Promotion of sustainability management



31

We also recognize sustainability-oriented management as a key issue.

SHOFU has already established a basic sustainability policy and identified materiality issues as part of our commitment to building a sustainable society. We have been working toward the achievement of these goals, and going forward, we will continue to operate under this policy to realize our corporate philosophy.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Cost of capital and share price conscious management①



Current status

- ROE exceeds cost of equity (equity spread is positive)
- PBR and PER are below the medical equipment sector average

Issues to address

- Fill gap for investors on perception of our Group's growth story
- Reduce liquidity risk

01

Improve return on capital

02

Improve stock liquidity

03

Improve IR activities

04

Clarify capital policies and enhance shareholder returns

For further details, please refer to the press release "[Measures to achieve cost of capital and share price conscious management \(UPDATE\)](#)" announced on May 9, 2025.

32

Next, I would like to explain our views and initiatives regarding management that takes capital cost and stock price into consideration. For further details, please refer to the press release published on May 9 titled, "Actions Toward Management Conscious of Capital Cost and Stock Price."

To begin with a current assessment, while our ROE exceeds the cost of shareholders' equity, our PBR and PER remain below the sector average, which we recognize as a serious issue. This implies a significant gap between our growth story and how it is perceived by the market. Bridging this gap is essential from the perspective of stock valuation.

In our conversations with investors, we have also frequently received comments on the low liquidity of our stock. We recognize that reducing liquidity risk is essential for achieving appropriate stock valuation.

Now I will outline our approach to implementing management that is conscious of capital cost and stock price.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Cost of capital and share price conscious management②



01 Improve return on capital

■ Increase return on capital by improving return on sales *↑/↓ indicate comparison to the initial plan

ROE	FYE3/24 Actual	FYE3/25 Actual	FYE3/26 forecast	FYE3/27 Plan	FYE3/28 Plan
	9.5%	10.3% ↑	10.9% ↑	11.8%	13.5%

02 Improve stock liquidity

- ▶ Recognition of Issues at the Time of Medium-Term Plan Formulation
 - In FYE3/24, the average daily trading value was ¥65 million, with an annual turnover ratio of 0.37x. Among Prime Market-listed companies, we ranked 1,428th (bottom 15%).
 - Recognizing that our relatively low liquidity has led to a liquidity risk premium being added to our capital cost, we identified improving market liquidity as a priority issue.
- ▶ Initiatives in FYE3/25
 - Implemented a 2-for-1 stock split of common shares (effective October 1, 2024)
 - Conducted overseas IR roadshows (Europe: UK, France, Switzerland, Germany, Sweden)
 - Enhanced IR practices, including simultaneous Japanese-English disclosures
- ▶ Improvement Status as of End of FYE/25
 - In FYE3/25, the average daily trading value increased to ¥215 million, with an annual turnover ratio of 0.77x. We ranked 963rd among Prime Market-listed companies (top 59%).
 - The number of shareholders at end FYE3/25 was 18,718, an increase of 4,945 compared to end FYE3/24.

Progress in improving liquidity
—an essential step toward reducing capital costs. Efforts will continue.

33

First, regarding improvement in capital efficiency, in FY2024, the final year of the previous medium-term management plan, our ROE was 9.5%. Under the current plan, we had projected 9.1% for FY2025 and 10.2% for FY2026. However, actual results and updated forecasts are now 10.3% and 10.9%, respectively, both exceeding initial expectations.

We aim to maintain this upward trend and achieve an ROE of 13.5% in FY2028, the final year of the plan. This improvement in ROE will come from better net profit margins, not from reducing equity. We will continue to work toward increasing capital efficiency through improved profitability.

Next, regarding improved stock liquidity. As of FY2024, SHOFU ranked in the bottom 15% of companies listed on the Prime Market in terms of average daily trading value and annual turnover rate.

This low liquidity has likely resulted in a liquidity risk premium being added to our capital cost, and we recognize the urgency of addressing this issue.

In response, we carried out a two-for-one stock split effective September 30, 2024. By lowering the minimum investment amount, we aim to reduce barriers for individual investors and encourage those who already use our products to also support us as shareholders.

In addition, we are enhancing our global investor relations efforts, including simultaneous English-language disclosures and overseas roadshows, to improve awareness among international investors.

As a result of these efforts, both average daily trading value and turnover rate improved in FY2025, and SHOFU's position rose to the top 59% among Prime Market-listed companies. We will continue these efforts to reduce our capital cost and enhance corporate value.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Cost of capital and share price conscious management③



03

Improve IR activities

▶ Efforts to date for promote dialogue with investors	[Efforts to date] <ul style="list-style-type: none"> • Hold results briefings for analysts and institutional investors (twice a year: Q2 and full-year results) • 1-on-1 meetings are mainly with the executives in charge of Corporate Planning (98 meetings in FYE3/24, including 34 with foreign investors)
▶ Future policy	[Future policy] <ul style="list-style-type: none"> • President & COO to attend more 1-on-1 meetings • Exploring participation of outside directors in investor engagement • Strengthen the functions of the department in charge of IR • Strengthen approach to foreign investors by holding overseas roadshows, etc. • Timely disclosure to foreign investors enhanced through simultaneous release of Japanese and English materials.
▶ Initiatives During FYE3/2025	<ul style="list-style-type: none"> • Conducted overseas roadshows (Europe, twice; total 8 days; 23 institutions) • Held technical briefings for institutional investors (small-group meetings) • President actively participated in 1-on-1 meetings • Disclosed supplementary presentation materials for 1Q and 3Q, for which no earnings briefings are held
▶ Key Changes in FYE3/2025	<ul style="list-style-type: none"> • Held 262 1-on-1 meetings (incl. 112 with foreign investors), approx. 3x vs the previous FYE • Foreign ownership ratio increased to 13.4% (up 0.76 percentage points year on year) • Increased analyst coverage, with coverage started at two new firms: Mizuho Securities and Nomura Securities
▶ Initiative Plans Beyond FYE3/2026	<ul style="list-style-type: none"> • Quarterly earnings briefings held for analysts and institutional investors • English disclosures of the Annual Securities Report and Corporate Governance Report • English mirror version of the Japanese IR website planned • Regular overseas roadshows planned (including the US, Europe, and Asia) • Dialogue planned between investors and outside directors

34

Through ongoing dialogue with investors, we are also reinforcing our IR activities. In FY2025, the number of one-on-one meetings with institutional investors increased nearly threefold compared to the previous year. Notably, we had many opportunities to engage with overseas investors, and we are experiencing a clear expansion in interest toward SHOFU.

Additionally, coverage by sell-side analysts has increased, creating a broader environment in which more investors can access information about our company.

We will continue to actively create such opportunities for dialogue.

As President and CEO, I will personally take the lead in engaging in open and constructive conversations with all stakeholders, with the goal of further enhancing our corporate value.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Cost of capital and share price conscious management④



04

Clarify capital policies and enhance shareholder returns

- We will make record growth investments, mainly related to production. Funds will be allocated from operating CF generated during the medium-term management plan, sales of strategic shareholdings, and debt financing
- Enhance shareholder returns

Aggressive investment in growth	Sale of strategic shareholdings	Enhanced shareholder returns
Increase production capacity <ul style="list-style-type: none"> ● Kyoto head office plant (filling and restorative materials) ● 2 domestic production sites Expansion of facilities, reallocation of production between parent and subs ● Establish 2nd production site in China ● Vietnam plant expansion <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Total ¥9bn over 4 years (Excludes investment in logistics for overseas sales bases) </div>	Holdings as of end-FYE3/24 Number of companies: 14 Market value: ¥8,899 mn*. Ratio of holdings to net assets: approx. 20%. <div style="border: 1px solid black; padding: 2px; margin-top: 5px; display: inline-block;"> To be sold: ¥4,000mn </div> Holdings as of end-FYE3/28 (plan) Market value: approx. ¥4,899mn* Ratio of holdings to net assets: approx. 10%. <small>*Market value as of end-FYE3/24.</small>	Previous benchmark Consolidated dividend payout ratio: 30% or more DOE: 1.7% or more <div style="border: 1px solid black; padding: 2px; margin-top: 10px; display: inline-block;"> Dividend payout ratio +10ppt DOE +1.3ppt </div> New benchmark Consolidated dividend payout ratio: 40% or more DOE: 3.0% or more

Further details on investments: p30

35

Clarifying our capital policy and enhancing shareholder returns is one of the most important messages we wish to convey today.

Based on feedback from our dialogues with investors regarding the level of our equity capital, we are aiming to optimize our capital structure and achieve sustainable enhancement of corporate value by allocating capital, with a balanced focus on growth investment, shareholder returns, and strengthening of the management foundation.

In this medium-term management plan, we are particularly focusing on three pillars to improve capital efficiency, capital investment for growth, the sale of policy-holding shares, and the enhancement of shareholder returns.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



30

Cost of capital and share price conscious management⑤



Focus: Sales of cross shareholding



- Improve capital efficiency by using the sale proceeds to fund growth investments
- As of end FYE3/2025, ratio of cross-shareholdings to net assets was 11.4%
- As of end FYE3/25, divestment of four stocks and partial divestment of one stock was completed of the stocks held at the beginning of the period
- The number of shares of the Company held as strategic shareholdings by other institutions decreased by 1.732 million shares (4.8% of the total number of issued shares).

36

Now let me provide a deeper look into our progress on the sale of policy-holding shares in the first year.

In FY2025, the actual proceeds from the sale of such shares amounted to JPY869 million, significantly exceeding our initial target of JPY600 million.

Specifically, we sold all shares in four holdings and partially sold one additional holding. As a result, the ratio of policy-holding shares to net assets dropped to 14.4% as of the end of the fiscal year, indicating steady progress toward our medium-term goal of reducing this ratio to around 10%.

Additionally, shares of SHOFU held by counterparties declined by 4.8% of total issued shares, showing tangible progress in dissolving cross-shareholdings.

We will continue to review and act accordingly, as part of our efforts to manage with capital efficiency and capital cost in mind.

Support

Japan 050.5212.7790
Tollfree 0120.966.744


Email Support support@scriptsasia.com



Cost of capital and share price conscious management



Capital allocation



- Against FY3/25-28 operating CF of ¥17.6bn, plan to invest ¥15.3bn in capex, including growth investments, and return ¥7.4bn to shareholders including a higher dividend payout ratio
- Investments in excess of operating CF are to be met by a reduction in strategic shareholdings and interest-bearing debt. Net cash (cash and deposits + investment securities - interest-bearing debt) is expected to decrease by ¥5.8bn

37

This chart shows an overview of our capital allocation, from FY2024 through FY2028. While operating cash flow will be our primary funding source, we will also combine proceeds from the sale of policy-holding shares and appropriate debt financing to allocate funds for growth investments and shareholder returns.

Over this period, we project cumulative operating cash flow of approximately JPY17.6 billion. Adding approximately JPY4 billion from the sale of policy-holding shares and debt financing, we expect to manage a total of around JPY23 billion in capital.

As a result, net cash is expected to decline by about JPY5.8 billion. However, this is a strategic allocation aimed at improving capital efficiency, and we believe our financial soundness will remain well within an acceptable range.

We also plan to reduce excess cash-on-hand, which we had maintained somewhat conservatively in the past, to around 2 to 2 1/2 months' worth of monthly sales by the final year of the plan. This will help raise ROE and capital efficiency.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com



Setting out a new vision

- As we celebrate our 100th anniversary, we need a new vision for the next 100 years in order to continue to grow and evolve
- Proactively invest overseas, where growth will be focused, through a strong domestic business base. Aim for continuous business expansion by increasing market share in developed countries and capturing new markets in emerging countries
- Our previous long-term vision of group sales of ¥50bn* is but a milestone, we **will become a top 10 global dental equipment & materials company**
- Current management and next generation leaders will play a central role in setting KPIs and shaping how we intend to take on the next 100 years

*In addition to group sales of ¥50bn, we also targeted operating income of ¥7.5bn (operating margin: 15%)

39

Finally, I would like to touch on our initiatives toward formulating our next long-term vision.

Under the current medium-term management plan, we have focused on achieving the long-term vision formulated in 2024, our “JPY50 billion Concept,” and laying the groundwork for sustainable business expansion beyond that milestone.

Now as we stand at this turning point, we have begun work on a new vision for the future. Our executive team, along with a new generation of future leaders, is engaging in serious discussions about the future direction of the Company.

Our shared ambition is to become one of the top 10 companies in the global dental equipment market.

With a clear focus on our global market positioning, we are committed to further enhancing the competitiveness of our products and the value we provide.

While we had hoped to present the full picture of this new vision today, we have decided to proceed with caution in light of recent uncertainty and rapid environmental change. We will share the full details with you once preparations are complete.

To all our investors, we sincerely hope you will look forward to SHOFU’s continued evolution and growth. We also ask for your ongoing candid feedback and constructive dialogue.

That concludes my presentation. Thank you very much for your attention throughout.

Moderator: Thank you very much.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptasia.com

Question & Answer

Moderator [M]: We will now move on to the Q&A session. The following question will be read aloud. As the participant has requested anonymity, we will read only the question itself.

Participant [Q]: Regarding the nail business, it recorded operating losses for five consecutive quarters, from Q3 FY2024 through Q3 FY2025, and although it returned to profitability in Q4, the business appears to have a fragile foundation. Since you are promoting management that is conscious of capital cost and stock price, and have declared a policy to sell policy-holding shares, could you please share your thoughts on the future direction of the nail business?

Takami [A]: Thank you. Let me explain our position on the nail business. It is true that our nail business has been facing considerable challenges. We recognize the need to consider various options, including the future outlook of the business.

We feel a strong sense of urgency that continuing the business in its current state will be difficult. We are therefore examining restructuring measures that include rebuilding distribution channels, revising pricing, and organizational reforms.

At this stage, we have not yet seen clear numerical improvements. However, we do see some potential, such as the resumption of business with major dealers, price adjustments, and new distribution channels overseas, and we intend to carefully assess these possibilities.

We plan to observe throughout this fiscal year whether our initiatives can steadily lead to results and make our decisions accordingly. Thank you.

Moderator [M]: Thank you very much. Let us proceed to the next question.

Participant [Q]: Isn't your forecast for this fiscal year overly conservative due to exchange rate assumptions? Doesn't this pose a risk of misleading expectations regarding performance?

Takami [M]: Thank you for the question. I'll ask our Senior Executive Officer, Mr. Yamazaki, to address this.

Yamazaki [A]: Thank you for the question. We are aware that the YoY decline in operating profit forecast for this fiscal year makes it difficult to explain our outlook both internally and externally. As part of the IR team, we are handling this matter with care to avoid any misunderstanding.

Internally, the initial exchange rate assumptions were weaker than what we ultimately adopted. However, just before finalizing the plan, the yen appreciated significantly, and we revised our assumption to JPY140 to align with the medium-term management plan. As a result, the impact of foreign exchange fluctuations led to a JPY625 million negative effect on operating profit. Had it not been for this, we would have seen a narrative of continuous operating profit growth.

That said, as mentioned in the presentation, our growth trend and the overall business environment remain solid, and we feel confident. In fact, we are forecasting record-high net sales, and we intend to explain this thoroughly through briefings like today and individual meetings. That concludes my response.

Moderator [M]: Thank you very much. We will now move on to the next question.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasia.com

Participant [Q]: While other companies are struggling in the Chinese market, SHOFU seems unaffected. What is the reason for this?

Takami [A]: Thank you for the question. In the Chinese market overall, there does appear to be some impact from the economic slowdown. However, for SHOFU, we have not seen any significant negative effect on our performance so far, and we are continuing to grow steadily.

In terms of the product categories involved, within the dental field, it appears that products related to capital investment [inaudible] longer replacement cycles, and restrained capital expenditures are leading to declines in sales. However, our main product lineup consists of dental materials used in daily clinical practice. Since we primarily handle consumables, demand has remained relatively stable.

Our high value-added products currently face limited competition from Chinese companies, as there are few offerings of comparable quality and value. This gives us a certain competitive advantage.

Most importantly, SHOFU entered the Chinese market early, around 1997. Since then, we have held numerous seminars and engaged directly with end users, earning recognition for the SHOFU brand. As a result, our brand enjoys solid awareness in the Chinese market.

Given these conditions, we are currently maintaining stable growth in the region.

Moderator [M]: Thank you very much. We will now move on to the next question.

Participant [Q]: What are the key KPIs that support your target of achieving ROE of 13.5% by 2028?

Takami [M]: I'll have Mr. Yamazaki explain that as well.

Yamazaki [A]: Thank you for the question. In our current medium-term management plan, we have set a target of achieving 13.5% ROE in FY2028. To achieve this, we are focusing on three main metrics, improvement in operating profit margin, enhancement of asset turnover, and better capital efficiency.

Specifically, we are shifting toward higher-margin product groups, improving operating profit margin through more efficient manufacturing, and targeting a 15% operating profit margin by FY2028.

We are also working to optimize working capital in line with sales growth and improve asset turnover by strengthening inventory and accounts receivable management. Additionally, we aim to improve capital efficiency through the sale of policy-holding shares and the strategic use of equity capital.

Through these efforts, we are aiming to build ROE steadily by enhancing both profitability and capital efficiency. We will also regularly monitor financial KPIs, such as operating profit margin, ROA, and dividend payout ratio, to ensure we stay on track toward achieving our goals. That concludes my response.

Moderator [M]: Thank you very much. If you still have any questions, please feel free to use the Q&A function to submit them. We will now proceed to the next question.

Participant [Q]: The archaeological excavation cost was recorded as a onetime expense. Is there a risk of additional costs arising in subsequent construction phases?

Takami [A]: I will respond to that. The archaeological excavation expense recorded in FY2025 was a temporary outlay associated with the legally required survey conducted during the first phase of the reconstruction project at our headquarters factory.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptasia.com



The second phase of construction is planned immediately adjacent to the first phase area. While a similar excavation survey may be required, the area is nearly identical to the first phase. Therefore, even if costs do arise, we expect them to be relatively minor.

Additionally, a portion of the excavation costs is expected to be subsidized by the City of Kyoto. Although no amount has been confirmed yet for this fiscal year, partial cost recovery is anticipated.

Most importantly, we view the excavation-related costs as one-off and limited in scope. They will have minimal impact on our ongoing cost structure. That concludes my response.

Moderator [M]: Thank you. We will now read the next question.

Participant [Q]: This year's performance is impacted by yen appreciation, but even excluding the FX effect, operating profit margin is forecast to decline. Could you explain the reasons behind this margin decrease in FY2026, especially considering your forecast that it will rise again from FY2027?

Takami [A]: Thank you. The factors behind the decline in operating profit margin this fiscal year, even excluding the impact of exchange rates, primarily relate to personnel costs. We are increasing our sales personnel, especially in overseas markets, which naturally raises costs.

In emerging markets, in particular, we are looking to strengthen our distribution network and assign sales staff to expand further.

These investments are contributing to a slight decline in the operating margin this year. However, we consider this cost increase to be an investment for future growth, which is why we forecast operating profit margin to rise again from FY2027 onward. That is all from me.

Moderator [M]: Thank you very much. That concludes the Q&A session for today.

To close, President Takami will deliver a final message.

Takami [M]: Thank you all very much for staying with us until the end of today's session. At SHOFU, while our domestic business is important, we see overseas markets as our main battleground going forward. We are confident that we can take further leaps internationally.

We welcome your continued opinions and feedback. Thank you again for your support.

Moderator [M]: That concludes SHOFU INC.'s financial results briefing for the fiscal year ended March 2025.

Thank you very much for your participation today.

[END]

Document Notes

1. Portions of the document where the audio is unclear are marked with [inaudible].
2. Portions of the document where the audio is obscured by technical difficulty are marked with [TD].
3. Speaker speech is classified based on whether it [Q] asks a question to the Company, [A] provides an answer from the Company, or [M] neither asks nor answers a question.
4. This document has been translated by SCRIPTS Asia.

Support

Japan 050.5212.7790
Tollfree 0120.966.744

Email Support support@scriptsasias.com



Disclaimer

SCRIPTS Asia reserves the right to edit or modify, at its sole discretion and at any time, the contents of this document and any related materials, and in such case SCRIPTS Asia shall have no obligation to provide notification of such edits or modifications to any party. This event transcript is based on sources SCRIPTS Asia believes to be reliable, but the accuracy of this transcript is not guaranteed by us and this transcript does not purport to be a complete or error-free statement or summary of the available data. Accordingly, SCRIPTS Asia does not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information contained in this event transcript. This event transcript is published solely for information purposes, and is not to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal.

In the public meetings and conference calls upon which SCRIPTS Asia's event transcripts are based, companies may make projections or other forward-looking statements regarding a variety of matters. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in the applicable company's most recent public securities filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are accurate and reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the anticipated outcome described in any forward-looking statements will be realized.

THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE PUBLIC MEETING OR CONFERENCE CALL. ALTHOUGH SCRIPTS ASIA ENDEAVORS TO PROVIDE ACCURATE TRANSCRIPTIONS, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE TRANSCRIPTIONS. IN NO WAY DOES SCRIPTS ASIA OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BY ANY PARTY BASED UPON ANY EVENT TRANSCRIPT OR OTHER CONTENT PROVIDED BY SCRIPTS ASIA. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S PUBLIC SECURITIES FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS. THIS EVENT TRANSCRIPT IS PROVIDED ON AN "AS IS" BASIS. SCRIPTS ASIA DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, AND ACCURACY, COMPLETENESS, AND NON-INFRINGEMENT.

None of SCRIPTS Asia's content (including event transcript content) or any part thereof may be modified, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of SCRIPTS Asia. SCRIPTS Asia's content may not be used for any unlawful or unauthorized purposes.

The content of this document may be edited or revised by SCRIPTS Asia at any time without notice.

Copyright © 2025 SCRIPTS Asia K.K. ("SCRIPTS Asia"), except where explicitly indicated otherwise. All rights reserved.

Support

Japan 050.5212.7790

Tollfree 0120.966.744

Email Support support@scriptsasia.com

